Aligos Therapeutics (ALGS) Other Non-Current Assets (2019 - 2026)
Aligos Therapeutics (ALGS) reported Other Non-Current Assets of $759000.0 for Q1 2026, up 20.09% on a YoY basis from $632000.0 in Q1 2025, and up 6.15% quarter-over-quarter from $715000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Other Non-Current Assets for 8 years, with the latest figure at $759000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 20.09% year-over-year to $759000.0; the trailing twelve-month figure through Mar 2026 stood at $759000.0 (up 20.09% YoY), and the FY2025 full-year result was $715000.0, up 14.04% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $759000.0, up from $715000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.6 million in Q1 2022, with the low at $21000.0 in Q2 2022.
- Historically, Other Non-Current Assets has averaged $466235.3 across 5 years, with a median of $627000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 89.12% — and 2024, when it surged 1402.38%.
- Aligos Therapeutics' Other Non-Current Assets stood at $115000.0 in 2022, then sank by 39.13% to $70000.0 in 2023, then surged by 795.71% to $627000.0 in 2024, then advanced by 14.04% to $715000.0 in 2025, then rose by 6.15% to $759000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $759000.0 (Q1 2026), $715000.0 (Q4 2025), and $713000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Aligos Therapeutics | 54.72 Mn | -25.11 Mn | - | 759,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 759,000.00 |
| Dec 31, 2025 | 715,000.00 |
| Sep 30, 2025 | 713,000.00 |
| Jun 30, 2025 | 640,000.00 |
| Mar 31, 2025 | 632,000.00 |
| Dec 31, 2024 | 627,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Jun 30, 2024 | 631,000.00 |
| Mar 31, 2024 | 216,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 397,000.00 |
| Dec 31, 2022 | 115,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 866,000.00 |
| Sep 30, 2021 | 653,000.00 |
| Jun 30, 2021 | 193,000.00 |